Esperion Therapeutics Inc. Common Stock (ESPR)

FairStock Score: 43/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable competitive advantages, conservative balance sheets, and a margin of safety. Esperion is a commercial-stage specialty drugmaker selling two cholesterol tablets, NEXLETOL and NEXLIZET, through a 294-person organization. That is a narrow product line, and the supplied data do not demonstrate a wide moat. In the latest reported quarter, fiscal Q1 2026, revenue was $80.1M but net income was -$25.2M, a -31.45% net margin. Trailing free cash flow is -$18.4M, with a FairStock-calculated FCF yield of -3.7%. The provided growth data are rapid, but FairStock cannot assign a Peter Lynch category because there are 0 years of filed annual results and it needs 3; without a filed track record, I cannot treat growth as durable. Financial health is poor: Piotroski F-Score 0/9 and Altman Z-Score -4.06 signal distress risk, though ROCE is 12.04% and beta is 1.06. At the 2026-07-14 close of $3.18, market cap is $503.2M. P/E and P/B are not applicable; EV/EBITDA is 7.54 per FairStock, which looks undemanding only if EBITDA is sustainable, yet cash flow is negative. FairStock Score is 43/100. The 52-week range of $1.80 to $4.18 shows volatility. I would want consistent annual filings, positive free cash flow, and a sturdier balance sheet before seeing a Graham-style bargain.

In plain English: Esperion makes cholesterol-lowering pills called NEXLETOL and NEXLIZET. The company is growing sales, but it still loses money and burns cash. At $3.18 a share, the price looks speculative: it is not clearly cheap based on the numbers, and the business looks financially weak.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-07-14 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer